Serum HER-2/neu conversion to positive at the time of cancer progression in metastatic breast patients treated with letrozole vs. tamoxifen.

被引：0
|
作者：
Lipton, A
Leitzel, K
Ali, SM
Demers, L
Harvey, HA
Chaudri-Ross, HA
Lang, R
Hackl, W
Hamer, P
Carney, W
机构：
[1] Penn State Hershey Med Ctr, Lebanon VA Med Ctr, Hershey, PA USA
[2] Novartis Pharma AG, Basel, Switzerland
[3] Oncogene Sci Bayer Diagnost, Cambridge, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2003年 / 21卷 / 23期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：288S / 288S
页数：1
相关论文
共 50 条
  • [31] Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer
    Ali, Suhail M.
    Carney, Walter P.
    Esteva, Francisco J.
    Fornier, Monica
    Harris, Lyndsay
    Koestler, Wolfgang. J.
    Lotz, Jean-Pierre
    Luftner, Diana
    Pichon, Marie-France
    Lipton, Allan
    CANCER, 2008, 113 (06) : 1294 - 1301
  • [32] Clinical utility of an automated serum HER-2/neu assay in monitoring patients with metastatic breast cancer.
    Dai, J
    Morris, DL
    Neaman, IE
    Carney, W
    Tenny, D
    Yeung, KK
    Allard, WJ
    Chan, DW
    Schwartz, MK
    CLINICAL CHEMISTRY, 1998, 44 : A47 - A47
  • [33] Drug Holidays in Patients with HER-2 Positive Metastatic Breast Cancer
    Kurtom, Saba
    Senol, Kazim
    Sabih, Qurat Ul Ain
    Sezgin, Efe
    Brufsky, Adam
    Gorantla, Vikram
    Puhalla, Shannon
    Soran, Atilla
    CANCER RESEARCH, 2024, 84 (09)
  • [34] Serum HER-2/neu dynamics in metastatic breast cancer as an independent prognostic factor.
    Schippinger, W
    Bauernhofer, T
    Regitnig, P
    Ploner, F
    Krippl, P
    Hofmann, G
    Lax, S
    Carney, W
    Neumann, R
    Wernecke, KD
    Samonigg, H
    BREAST CANCER RESEARCH AND TREATMENT, 2003, 82 : S123 - S123
  • [35] Decreased survival after conversion to serum HER-2/neu positive.
    Lipton, A
    Leitzel, K
    Ali, SM
    Demers, L
    Harvey, HA
    Chaudri-Ross, H
    Lang, R
    Hackl, W
    Hamer, P
    Carney, W
    BREAST CANCER RESEARCH AND TREATMENT, 2003, 82 : S121 - S121
  • [36] HER-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer
    Konecny, GE
    Thomssen, C
    Lück, HJ
    Untch, M
    Wang, HJ
    Kuhn, W
    Eidtmann, H
    du Bois, A
    Olbricht, S
    Steinfeld, D
    Möbus, V
    von Minckwitz, G
    Dandekar, S
    Ramos, L
    Pauletti, G
    Pegram, MD
    Jänicke, F
    Slamon, DJ
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (15): : 1141 - 1151
  • [37] Her-2/neu and topoisomerase IIaexpression in primary and metastatic breast cancer
    Cardoso F.
    Breast Cancer Research, 3 (1)
  • [38] Evaluation of Serum HER-2/neu Extracelluar Domain in Breast Cancer Patients: Correlation with Tissue HER-2/neu Status and Clinicopathological Factors
    Kang, Sun Hee
    Cho, Jihyoung
    Ha, Jung Sook
    Kwon, Sun Young
    JOURNAL OF THE KOREAN SURGICAL SOCIETY, 2010, 78 (05): : 271 - 276
  • [39] Correlation of serum HER-2/neu extracellular domain levels in metastatic breast cancer with the expression of HER-2/neu determined by immunohistochemistry in primary tumors.
    Witzel, I
    Thomssen, C
    Pantel, K
    Neumann, R
    Carney, W
    Loening, T
    Jaenicke, F
    Mueller, V
    BREAST CANCER RESEARCH AND TREATMENT, 2003, 82 : S143 - S143
  • [40] Circulating tumor cells in HER-2 positive metastatic breast cancer patients treated with trastuzumab and chemotherapy
    Nunes, Raquel A.
    Li, Xiaochun
    Kang, Soonmo Peter
    Burstein, Harold
    Roberts, Lisa
    Carney, Walter
    Blackwell, Kimberly
    Ryan, Paula
    Borges, Virginia
    Iglehart, J. Dirk
    Friedman, Paula
    Harris, Lyndsay N.
    INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2009, 24 (01): : 1 - 10
12345